Fundamental Analysis of WINDTREE THERAPEUTICS INC(NASDAQ:WINT) stock

Fundamental Rating

We assign a fundamental rating of 0 out of 10 to WINT. WINT was compared to 564 industry peers in the Biotechnology industry. WINT may be in some trouble as it scores bad on both profitability and health. WINT does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

WINT had negative earnings in the past year.

WINT had a negative operating cash flow in the past year.

In the past 5 years WINT always reported negative net income.

In the past 5 years WINT always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of WINT (-39.66%) is comparable to the rest of the industry.

With a Return On Equity value of -108.96%, WINT perfoms like the industry average, outperforming 43.45% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-39.66%
ROE	-108.96%
ROIC	N/A

ROA(3y)-85.45%

ROA(5y)-61.66%

ROE(3y)-383.83%

ROE(5y)-246.99%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

WINT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

WINT has more shares outstanding than it did 1 year ago.

WINT has more shares outstanding than it did 5 years ago.

WINT has a worse debt/assets ratio than last year.

2.2 Solvency

WINT has an Altman-Z score of -44.40. This is a bad value and indicates that WINT is not financially healthy and even has some risk of bankruptcy.

WINT has a worse Altman-Z score (-44.40) than 94.08% of its industry peers.

A Debt/Equity ratio of 0.15 indicates that WINT is not too dependend on debt financing.

The Debt to Equity ratio of WINT (0.15) is worse than 67.15% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.15
Debt/FCF	N/A
Altman-Z	-44.4

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 0.23 indicates that WINT may have some problems paying its short term obligations.

The Current ratio of WINT (0.23) is worse than 96.77% of its industry peers.

WINT has a Quick Ratio of 0.23. This is a bad value and indicates that WINT is not financially healthy enough and could expect problems in meeting its short term obligations.

WINT has a Quick ratio of 0.23. This is amonst the worse of the industry: WINT underperforms 96.41% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.23
Quick Ratio	0.23

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.53% over the past year.

EPS 1Y (TTM)99.53%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-544.19%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, WINT will show a very negative growth in Earnings Per Share. The EPS will decrease by -10.26% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y69.66%

EPS Next 2Y31.47%

EPS Next 3Y24.34%

EPS Next 5Y-10.26%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for WINT. In the last year negative earnings were reported.

Also next year WINT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as WINT's earnings are expected to grow with 24.34% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y31.47%

EPS Next 3Y24.34%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

WINT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

WINDTREE THERAPEUTICS INC

NASDAQ:WINT (1/3/2025, 8:10:31 PM)

After market: 0.3132 -0.01 (-1.69%)

0.3186

-0.02 (-6.02%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-26 2024-11-26/amc

Earnings (Next)N/A N/A

Inst Owners1.42%

Inst Owner Change10655.2%

Ins Owners0.68%

Ins Owner Change0.01%

Market Cap2.86M

Analysts43.33

Price Target7.14 (2141.05%)

Short Float %5.55%

Short Ratio0.33

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.27
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-8

EYN/A

EPS(NY)-2.17

Fwd EYN/A

FCF(TTM)-1.42

FCFYN/A

OCF(TTM)-1.41

OCFYN/A

SpS0

BVpS1.16

TBVpS-1.65

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-39.66%
ROE	-108.96%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-85.45%

ROA(5y)-61.66%

ROE(3y)-383.83%

ROE(5y)-246.99%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.15
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	33.33%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.23
Quick Ratio	0.23
Altman-Z	-44.4

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)55.35%

Cap/Depr(5y)88.07%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)99.53%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-544.19%

EPS Next Y69.66%

EPS Next 2Y31.47%

EPS Next 3Y24.34%

EPS Next 5Y-10.26%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-66.23%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y43.4%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y42.78%

OCF growth 3YN/A

OCF growth 5YN/A

WINDTREE THERAPEUTICS INC (WINT)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens